ADORA2A and neoplasm: Phase 1 clinical trials (NCT03207867, NCT03549000) testing the A2A adenosine receptor inhibitor taminadenant (NIR178) with anti-PD-1 spartalizumab and/or anti-CD73 fully human antibody NZV930 were accruing patients with pancreatic cancer and many other tumor types, but no data have yet been reported.